Coccidioidomycosis natural history: Difference between revisions

Jump to navigation Jump to search
m (Bot: Removing from Primary care)
 
(9 intermediate revisions by 4 users not shown)
Line 3: Line 3:
{{Coccidioidomycosis}}
{{Coccidioidomycosis}}
==Overview==
==Overview==
Coccidioidomycosis is usually a self-limited mild clinical illness. A large proportion of individuals are clinically infected without any manifestations and are thus completely asymptomatic. The remaining develop a mild pulmonary illness which in most cases is self limited requiring no treatment, and even those cases which do require treatment have an excellent prognosis. It is often misdiagnosed as community-acquired pneumonia. In a few cases, the clinical picture may be complicated due to widespread dissemination of the organism leading to a number of complications  [[Pleural effusion]], ([[relapse]], [[Meningitis]], [[pyopneumothroax]], hemoptysis, and pleuritic chest pain, [[Synovitis]] and [[Osteomyelitis]].
Coccidioidomycosis is usually a self-limited mild clinical illness. A large proportion of individuals are clinically infected without any manifestations and are thus completely asymptomatic. The remaining develop a mild [[pulmonary illness]] which in most cases is self-limited requiring no treatment, and even those cases which do require treatment have an excellent prognosis. The mortality rate is currently <0.07%. If left untreated in patients with weakened [[immune systems]], the [[infection]] spreads throughout the body. The clinical picture may be complicated due to widespread dissemination of the [[organism]] leading to a number of complications  [[pleural effusion]], [[relapse]], pyopneumothorax, [[hemoptysis]], and [[pleuritic chest pain]], [[synovitis]] and [[osteomyelitis]].


==Natural History==
==Natural History==
*Coccidioidomycosis is usually a self-limited mild clinical illness.
*[[Coccidioidomycosis]] is usually a self-limited mild clinical illness.
*A large proportion of individuals are clinically infected without any manifestations and are thus completely asymptomatic.  
*A large proportion of individuals are clinically infected without any manifestations and are thus completely asymptomatic.  
*The remaining develop a mild pulmonary illness which in most cases is self limited requiring no treatment, and even those cases which do require treatment have an excellent prognosis.  
*The remaining develop a mild pulmonary illness which in most cases is self-limited requiring no treatment, and even those cases which do require treatment have an excellent prognosis.  
*It is often misdiagnosed as [[community-acquired pneumonia]]. There are several cutaneous manifestations such as [[erythema multiforme]] and [[erythema nodosum]], it may even cause [[arthritis]] and [[arthralgias]].
*It is often misdiagnosed as [[community-acquired pneumonia]]. There are several [[cutaneous]] manifestations such as [[erythema multiforme]] and [[erythema nodosum]], it may even cause [[arthritis]] and [[arthralgias]].
*If left untreated in patients with weakened immune systems,the infection spreads throughout the body.
*If left untreated in patients with weakened [[immune systems]], the [[infection]] spreads throughout the [[body]].
*The disseminated form of ''Coccidioidomycosis'' can devastate the body, causing skin ulcers, [[abscess]]es, bone lesions, swollen joints with severe pain, heart inflammation, [[urinary tract]] problems, and [[meningitis|inflammation of the brain's lining]], which can lead to death.<ref>Galgiani J. N. Coccidioidomycosis. In: Cecil, Russell L., Lee Goldman, and D. A. Ausiello. Cecil Medicine. Philadelphia: Saunders Elsevier, 2007.</ref>
*The disseminated form of ''Coccidioidomycosis'' can devastate the body, causing [[skin]] [[ulcers]], [[abscess]]es, [[bone]] [[lesions]], [[Arthritis|swollen joints with severe pain]], [[pericarditis]], [[prostatitis]],[[urinary tract infection]], and [[meningitis|meningitis]], which can lead to death.<ref>Galgiani J. N. Coccidioidomycosis. In: Cecil, Russell L., Lee Goldman, and D. A. Ausiello. Cecil Medicine. Philadelphia: Saunders Elsevier, 2007.</ref>


==Complications==
==Complications==
Complications of [[coccidioidomycosis]] include:<ref name="Angelo-">{{Cite journal  | last1 = Angelo | first1 = KM. | last2 = Nnedu | first2 = ON. | title = Rare manifestations of coccidioidomycosis. | journal = J La State Med Soc |volume = 165 | issue = 3 | pages = 137-9 | month =  | year =  | doi =  | PMID = 24015425 }}</ref><ref name="Remesar-">{{Cite journal  | last1 = Remesar | first1 = MC. | last2 = Blejer | first2 = JL. | last3 = Negroni | first3 = R. | last4 = Nejamkis | first4 = MR. | title = Experimental coccidioidomycosis in the immunosuppressed rat. | journal = Rev Inst Med Trop Sao Paulo | volume = 34 | issue = 4 | pages = 303-7 | month =  | year =  | doi =  | PMID = 1342086 }}</ref>
Complications of [[coccidioidomycosis]] include:<ref name="Angelo-">{{Cite journal  | last1 = Angelo | first1 = KM. | last2 = Nnedu | first2 = ON. | title = Rare manifestations of coccidioidomycosis. | journal = J La State Med Soc |volume = 165 | issue = 3 | pages = 137-9 | month =  | year =  | doi =  | PMID = 24015425 }}</ref><ref name="Remesar-">{{Cite journal  | last1 = Remesar | first1 = MC. | last2 = Blejer | first2 = JL. | last3 = Negroni | first3 = R. | last4 = Nejamkis | first4 = MR. | title = Experimental coccidioidomycosis in the immunosuppressed rat. | journal = Rev Inst Med Trop Sao Paulo | volume = 34 | issue = 4 | pages = 303-7 | month =  | year =  | doi =  | PMID = 1342086 }}</ref>
* [[Pleural effusion]]
* [[Pleural effusion]]
* Return of the infection ([[relapse]]
* Return of the [[infection]] ([[relapse]])
* [[Meningitis]]
* [[Meningitis]]
* Pulmonary cavities, that may rupture leading to [[pyopneumothroax]], otherwise causing persistent cough, hemoptysis, and pleuritic chest pain.
* [[Pulmonary]] [[cavities]], that may [[rupture]] leading to [[Pneumothorax|pyopneumothroax]], otherwise causing persistent [[cough]], [[hemoptysis]], and [[pleuritic chest pain]]
* [[Synovitis]] and [[Osteomyelitis]].
* [[Synovitis]] and [[osteomyelitis]]


==Prognosis==
==Prognosis==
The prognosis of  Coccidioidomycosis is good in immunocompetent patients. It is self-limited in most of the patients and recovery is without any complications. The mortality rate is currently <0.07%. Approximately less than 1 % of patients develop disseminated coccidioidomycosis.
The prognosis of  Coccidioidomycosis is good in [[immunocompetent]] patients. It is self-limited in most of the patients and recovery is without any complications. The mortality rate is currently <0.07%. Approximately less than 1 % of patients develop disseminated [[coccidioidomycosis]].


Factors associated with poor prognosis:
Factors associated with poor prognosis:
*HIV disease,with low CD4 count (<250)
*[[HIV AIDS|HIV disease]],with low CD4 count (<250)
*Late stage Pregnancy( third trimester)
*Late stage [[Pregnancy]]( third trimester)
*Organ transplantation
*[[Organ transplantation]]
*Immunosuppresant therapy <ref name="pmid15188373">{{cite journal |vauthors=Bergstrom L, Yocum DE, Ampel NM, Villanueva I, Lisse J, Gluck O, Tesser J, Posever J, Miller M, Araujo J, Kageyama DM, Berry M, Karl L, Yung CM |title=Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists |journal=Arthritis Rheum. |volume=50 |issue=6 |pages=1959–66 |year=2004 |pmid=15188373 |doi=10.1002/art.20454 |url=}}</ref>
*[[Immunosuppressant therapy]] <ref name="pmid15188373">{{cite journal |vauthors=Bergstrom L, Yocum DE, Ampel NM, Villanueva I, Lisse J, Gluck O, Tesser J, Posever J, Miller M, Araujo J, Kageyama DM, Berry M, Karl L, Yung CM |title=Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists |journal=Arthritis Rheum. |volume=50 |issue=6 |pages=1959–66 |year=2004 |pmid=15188373 |doi=10.1002/art.20454 |url=}}</ref>


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
{{WH}}
{{WS}}
[[Category:Pulmonology]]
[[Category:Pulmonology]]
[[Category:Needs content]]
[[Category:Needs content]]
[[Category:Fungal diseases]]
[[Category:Fungal diseases]]
[[Category:Biological weapons]]
[[Category:Biological weapons]]
[[Category:Disease]]
[[Category:Emergency medicine]]
[[Category:Up-To-Date]]
[[Category:Infectious disease]]
[[Category:Infectious disease]]
[[Category:Disease]]
{{WH}}
{{WS}}

Latest revision as of 21:00, 29 July 2020

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: ; Vidit Bhargava, M.B.B.S [2]

Coccidioidomycosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Coccidioides immitis
Coccidioides posadasii

Differentiating Coccidioidomycosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Coccidioidomycosis natural history On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Coccidioidomycosis natural history

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Coccidioidomycosis natural history

CDC on Coccidioidomycosis natural history

Coccidioidomycosis natural history in the news

Blogs on Coccidioidomycosis natural history

Directions to Hospitals Treating Coccidioidomycosis

Risk calculators and risk factors for Coccidioidomycosis natural history

Overview

Coccidioidomycosis is usually a self-limited mild clinical illness. A large proportion of individuals are clinically infected without any manifestations and are thus completely asymptomatic. The remaining develop a mild pulmonary illness which in most cases is self-limited requiring no treatment, and even those cases which do require treatment have an excellent prognosis. The mortality rate is currently <0.07%. If left untreated in patients with weakened immune systems, the infection spreads throughout the body. The clinical picture may be complicated due to widespread dissemination of the organism leading to a number of complications pleural effusion, relapse, pyopneumothorax, hemoptysis, and pleuritic chest pain, synovitis and osteomyelitis.

Natural History

Complications

Complications of coccidioidomycosis include:[2][3]

Prognosis

The prognosis of Coccidioidomycosis is good in immunocompetent patients. It is self-limited in most of the patients and recovery is without any complications. The mortality rate is currently <0.07%. Approximately less than 1 % of patients develop disseminated coccidioidomycosis.

Factors associated with poor prognosis:

References

  1. Galgiani J. N. Coccidioidomycosis. In: Cecil, Russell L., Lee Goldman, and D. A. Ausiello. Cecil Medicine. Philadelphia: Saunders Elsevier, 2007.
  2. Angelo, KM.; Nnedu, ON. "Rare manifestations of coccidioidomycosis". J La State Med Soc. 165 (3): 137–9. PMID 24015425.
  3. Remesar, MC.; Blejer, JL.; Negroni, R.; Nejamkis, MR. "Experimental coccidioidomycosis in the immunosuppressed rat". Rev Inst Med Trop Sao Paulo. 34 (4): 303–7. PMID 1342086.
  4. Bergstrom L, Yocum DE, Ampel NM, Villanueva I, Lisse J, Gluck O, Tesser J, Posever J, Miller M, Araujo J, Kageyama DM, Berry M, Karl L, Yung CM (2004). "Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists". Arthritis Rheum. 50 (6): 1959–66. doi:10.1002/art.20454. PMID 15188373.

Template:WH Template:WS